Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly ...

RegRegon Pharmaceuticals and Sanofi recently announced that the European Commission approved Dupixent for treating moderate-to-severe chronic spontaneous urticaria in patients aged 12 and above who do ...

A new mold concept developed by Zahoransky is engineered to accelerate the mass production of housings for insulin pens and auto injectors in a space- and energy-efficient manner. The Z.Sonic turn ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) reported positive data from a late-stage trial, which assessed their asthma drug Dupixent (dupilumab) for treating allergic fungal rhinosinusitis in ...

Like any medication, Dupixent may cause various side effects. It’s especially known to cause side effects relating to the eyes, such as conjunctivitis, blepharitis, and keratitis. These side effects ...

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory conditions. For many, it has provided relief when other therapies failed. However, ...

Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the anti-inflammatory agent. Friday, Sanofi reported that Dupixent had set a ...

Sanofi SA (NASDAQ:SNY) reported third-quarter sales of $14.55 billion (12.43 billion euros), beating the consensus of $14.46 billion. Sales increased 2.3% year over year, up 7% in constant currency. U ...

Sanofi SAN-0.34%decrease; red down pointing triangle said a jump in sales of its blockbuster Dupixent drug and robust pharmaceutical launches drove higher revenue and adjusted earnings for the third ...